Abstract:An inherited neurodegenerative ailment called Huntington's disease (HD) of gradual physical impairment, cognitive decline, and psychiatric symptoms. It is brought on by a mutation of the HTT gene, which causes aberrant huntingtin protein buildup in neurons. This predominantly affects the striatum and cerebral cortex, where neuronal malfunction and eventual cell death follow. The quality index of life for both patients and their families is significantly impacted when symptoms first appear in mid-adulthood. An overview of the available therapies for HD is given in this article. Although HD has no known treatment options, there are several that try to lessen symptoms and reduce the disease's development. By lowering involuntary movements, pharmaceutical treatments like tetrabenazine and deutetrabenazine focus on motor symptoms. Antidepressants and antipsychotic medicines are also used to manage the mental and cognitive symptoms of HD. The investigation of prospective gene-based medicines is a result of research into disease-modifying medications. Reduced synthesis of mutant huntingtin protein is the goal of RNA interference (RNAi) strategies, which may halt the course of illness. Additionally, continuing research into Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-associated protein 9 (CRISPR-Cas9) and other gene editing methods shows promise for reversing the genetic mutation that causes HD. Individuals with HD can benefit from non-pharmacological therapies such as physical therapy, speech therapy, and occupational therapy to increase their functional abilities and general well-being. Supportive treatment, psychiatric therapy, and caregiver support groups are also essential in addressing the difficult problems the illness presents. In conclusion, tremendous progress is being made in the domain of HD treatment, with an emphasis on symptom control, disease modification, and prospective gene-based therapeutics. Even though there has been significant improvement, more study is still required to provide better therapies and ultimately discover a solution for this debilitating condition.

Huntington's Disease: Latest Frontiers in Therapeutics

Huntington Disease: Linking Pathogenesis to the Development of Experimental Therapeutics

Therapy development in Huntington disease: From current strategies to emerging opportunities

Latest Advances on New Promising Molecular-Based Therapeutic Approaches for Huntington’s Disease

Advances in Clinical Therapies for Huntington's Disease and the Promise of Multi-Targeted/Functional Drugs Based on Clinicaltrials.gov

Advances in Gene and Cellular Therapeutic Approaches for Huntington’s Disease

Exploring molecular mechanisms, therapeutic strategies, and clinical manifestations of Huntington's disease

Huntington’s Disease: Complex Pathogenesis and Therapeutic Strategies

Huntington's Disease: Molecular Basis of Pathology and Status of Current Therapeutic Approaches.

Huntington's Disease: Understanding Its Novel Drugs and Treatments

Progress in studies of gene therapy for Huntington's disease

Development of Novel Therapies for Huntington's Disease: Hope and Challenge1

Advancements in surgical treatments for Huntington disease: From pallidotomy to experimental therapies

Complex Pathogenesis and Therapeutic Strategies

Emerging pharmacological approaches for Huntington's disease

Huntington disease: natural history, biomarkers and prospects for therapeutics

Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities

Using gene or cell therapies to treat Huntington's disease

Unraveling the Puzzle of Therapeutic Peptides: A Promising Frontier in Huntington's Disease Treatment

The Huntington's disease drug pipeline: a review of small molecules and their therapeutic targets

Gene Targeting Techniques for Huntington’s Disease